Detalles de la búsqueda
1.
Outcomes of younger patients with mantle-cell lymphoma experiencing late relapse (>24 months): the LATE-POD study.
Blood
; 2024 05 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754055
2.
MYC protein is a high-risk factor in mantle cell lymphoma and identifies cases beyond morphology, proliferation and TP53/p53 - a Nordic Lymphoma Group study.
Haematologica
; 109(4): 1171-1183, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37646663
3.
Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established highrisk factors.
Haematologica
; 108(4): 1092-1104, 2023 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36519324
4.
Characterization and clinical impact of the tumor microenvironment in post-transplant aggressive B-cell lymphomas.
Haematologica
; 108(11): 3044-3057, 2023 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37259566
5.
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.
Haematologica
; 108(7): 1768-1781, 2023 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36519325
6.
Cancer risk and mortality after solid organ transplantation: A population-based 30-year cohort study in Finland.
Int J Cancer
; 150(11): 1779-1791, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35041762
7.
Thiopurine Enhanced ALL Maintenance (TEAM): study protocol for a randomized study to evaluate the improvement in disease-free survival by adding very low dose 6-thioguanine to 6-mercaptopurine/methotrexate-based maintenance therapy in pediatric and adult patients (0-45 years) with newly diagnosed B-cell precursor or T-cell acute lymphoblastic leukemia treated according to the intermediate risk-high group of the ALLTogether1 protocol.
BMC Cancer
; 22(1): 483, 2022 May 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35501736
8.
Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience.
Hematol Oncol
; 40(1): 22-30, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-34713465
9.
Efficacy of conventional-dose cytarabine, idarubicin and thioguanine versus intermediate-dose cytarabine and idarubicin in the induction treatment of acute myeloid leukemia: Long-term results of the prospective randomized nationwide AML-2003 study by the Finnish Leukemia Group.
Eur J Haematol
; 109(3): 257-270, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-35634931
10.
Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors.
Br J Haematol
; 193(3): 520-531, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33686666
11.
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma.
Br J Haematol
; 191(5): 796-805, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32748433
12.
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk.
BMC Cancer
; 20(1): 1202, 2020 Dec 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33287742
13.
TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.
Blood
; 130(17): 1903-1910, 2017 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-28819011
14.
Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.
Blood
; 128(14): 1814-1820, 2016 10 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27354719
15.
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Biol Blood Marrow Transplant
; 23(3): 428-435, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28039078
16.
Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
Blood
; 135(22): 2000-2004, 2020 05 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-32181815
17.
miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator.
Blood
; 125(17): 2669-77, 2015 Apr 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-25736311
18.
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
Br J Haematol
; 175(3): 410-418, 2016 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-27378674
19.
Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Blood
; 123(19): 2953-9, 2014 May 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-24652994
20.
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
Br J Haematol
; 166(1): 98-108, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24684350